Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of asthma and reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, prevention of exacerbations in COPD
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Oral: 200–400 mg every 6 hours; IV: 6 mg/kg loading dose over 30 minutes, then 0.4–0.6 mg/kg/h continuous infusion.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
The terminal elimination half-life of theophylline is approximately 8 hours in healthy non-smoking adults (range 3-12 hours). It is prolonged in patients with hepatic cirrhosis (up to 30 hours), heart failure (up to 30 hours), and in neonates (20-30 hours). Smoking (including marijuana) decreases half-life to 4-5 hours. Half-life is shorter in children (3-5 hours). Clinical context: Due to narrow therapeutic index, half-life variability necessitates therapeutic drug monitoring.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolized to 3-methylxanthine, 1,3-dimethyluric acid, and 1-methyluric acid.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Theophylline is primarily eliminated by hepatic metabolism (>90%), with only about 10-15% excreted unchanged in urine. Renal excretion of the parent drug is minor; however, metabolites are excreted renally. Biliary/fecal excretion accounts for less than 1%.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Theophylline is approximately 40% bound to plasma proteins, primarily albumin. Protein binding is decreased in neonates, patients with hepatic disease, and in the presence of unbound fatty acids.
65% bound to albumin
The apparent volume of distribution (Vd) of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg). This approximates total body water. Vd is increased in premature infants (0.6-0.8 L/kg) and patients with hepatic disease. Clinical meaning: Vd is used to calculate loading dose.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 96-100% (rapidly and completely absorbed). Oral sustained-release: 80-100% depending on formulation. Rectal enema: 80-100%. Rectal suppository: 70-90%. IV: 100%.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No adjustment necessary in renal impairment as theophylline is primarily hepatically metabolized. However, in severe renal failure (Cr Cl <10 m L/min), consider reducing dose by 25%.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: reduce dose by 25%; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% or avoid use.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Loading dose: 6 mg/kg IV; maintenance: <1 year: (0.2 x age in weeks) + 5 mg/kg/day divided q4-6h; 1-9 years: 20-24 mg/kg/day divided q4-6h; >9 years: 16 mg/kg/day divided q4-6h.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Elderly patients >60 years: reduce maintenance dose by 25-50% due to decreased clearance; monitor serum levels closely; target 5-15 mg/L.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
None. However, close monitoring of serum theophylline levels is required due to narrow therapeutic index.
No FDA black box warning.
Serum levels must be monitored to avoid toxicity (target 5-15 mcg/m L). Use with caution in patients with cardiac disease, seizure disorders, hepatic impairment, and elderly. Drug interactions (e.g., cimetidine, fluoroquinolones, macrolides) can increase levels. Smoking induces metabolism leading to decreased efficacy.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or any component; active seizure disorder; uncontrolled cardiac arrhythmias; peptic ulcer disease (relative).
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase central nervous system stimulation. Charcoal-broiled foods and high-protein/low-carbohydrate diets may increase clearance of theophylline, potentially reducing efficacy.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk of minor malformations based on animal data. Second and third trimesters: No evidence of major teratogenicity; risk of fetal tachycardia and irritability due to transplacental passage; avoid high doses near term.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Excreted into breast milk with M/P ratio approximately 0.6-0.9. Infant serum levels may reach therapeutic range at maternal doses >10 mg/kg/day; monitor infant for irritability or insomnia. Generally considered compatible with breastfeeding but use lowest effective dose.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Second and third trimesters: Increased clearance due to estrogen-induced hepatic metabolism; may require dose increase by 20-40% to maintain therapeutic levels. Postpartum: Clearance returns to prepregnancy levels within 2-4 weeks; reduce dose accordingly.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
SOMOPHYLLIN (theophylline) is a narrow therapeutic index drug; monitor serum levels (therapeutic range 5-15 μg/m L for asthma). Use with caution in patients with hepatic impairment, congestive heart failure, or elderly due to reduced clearance. Cigarette smoking and charcoal-broiled foods increase clearance, requiring dose adjustment. Concurrent use with cimetidine, fluoroquinolones, or macrolides can increase levels and toxicity.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and charcoal-grilled foods as they can affect drug levels.,Avoid caffeine-containing beverages and foods (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, palpitations, or seizures.,Missed dose: take as soon as remembered unless close to next dose; do not double dose.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN vs AEROLATE, answered by our medical review team.
SOMOPHYLLIN is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN is: Oral: 200–400 mg every 6 hours; IV: 6 mg/kg loading dose over 30 minutes, then 0.4–0.6 mg/kg/h continuous infusion.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk of minor malformations based on animal data. Second and third trimesters: No evidence of major. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.